Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions.
OBJECTIVE
There is a pressing need to determine the causes and consequences of, and optimal therapy for the chronic prostatitis-chronic pelvic pain syndrome.


METHODS
New data suggest that bacterial infection may be critical in some patients. We examined the rationale for and technical approaches to hypothesis driven studies of bacteria in the chronic prostatitis-chronic pelvic pain syndrome.


RESULTS
The first hypothesis was that patients with the chronic prostatitis-chronic pelvic pain syndrome have prostatic bacteria that distinguish them from controls. In pilot studies patients with inflamed expressed prostatic secretions were more likely to have bacterial DNAs, that is 16S ribosomal DNAs. Current goals are to clone, sequence and compare ribosomal DNAs from patients and controls to determine which bacteria are most specific to the chronic prostatitis-chronic pelvic pain syndrome and which should be targeted in clinical trials. The second hypothesis was that bacterial viability correlates with the severity of the chronic prostatitis-chronic pelvic pain syndrome. Quantitative assays for bacterial elongation factor messenger RNA (tufA messenger RNA) provide tools to correlate bacterial viability with patient characteristics, will provide insights into the potential value of antimicrobial therapy and identify characteristics that distinguish patients most likely to respond. The third hypothesis was that patients with prostatic bacteria have similar bacteria in expressed prostatic secretions or on seminal fluid analysis and, furthermore, these bacteria differ from bacteria in controls. These studies would determine whether expressed prostatic secretions or seminal fluid analysis can be used to identify prostatic bacteria and may result in clinical methods for noninvasive diagnosis of prostatic infection.


CONCLUSIONS
These studies should provide important insights into the causes of the chronic prostatitis-chronic pelvic pain syndrome and may elucidate optimal clinical evaluation and treatment in patients.
Krieger
John N
JN
Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Riley
Donald E
DE
D001419:Bacteria / Q000235:genetics / Q000302:isolation & purification*; D001424:Bacterial Infections / Q000150:complications / Q000175:diagnosis; D002908:Chronic Disease; D004269:DNA, Bacterial / Q000032:analysis; D004275:DNA, Ribosomal / Q000032:analysis; D006801:Humans; D008297:Male; D017699:Pelvic Pain / Q000382:microbiology*; D010444:Peptide Elongation Factor Tu / Q000235:genetics; D016133:Polymerase Chain Reaction; D011467:Prostate / Q000382:microbiology*; D011471:Prostatic Neoplasms / Q000382:microbiology; D011472:Prostatitis / Q000382:microbiology*; D012333:RNA, Messenger / Q000032:analysis; D013577:Syndrome
D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012333:RNA, Messenger; D010444:Peptide Elongation Factor Tu